Ready to Use Biosimilar Cell Lines

UGA has a constantly expanding portfolio of products in the area of cell biology, cell line development and biosimilar manufacturing. All products have been developed and evaluated in realistic scenarios and projects.

Cell Culture Medium

High Performance First CHOice® Medium and Feeds           
First CHOice® Medium is a high performance cell culture medium optimized for mammalian cell lines. In combination with CHOice® Feeds it has been optimized to boost the cell growth and productivity in batch, fed-batch and perfusion processes. The completely chemically defined, animal component and protein free medium has been developed in close cooperation with customers using CHO-S, CHO-DG44 and CHO-K1 cell lines in order to minimize stress-related metabolites such as lactate and ammonia. In this way high product quality and cell viability is guaranteed during all cultivation phases.
We request our clients to test this medium and feed for any projects in which titer needs to be increased together with maintaining consistent product quality attributes.
Please kindly see the attached exemplary data.


Adalimumab (HUMIRA®)           
Full package ready for sales now: 
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein
Aflibercept (ZALTRAP®)           
Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development is required to develop a biosimilar like Aflibercept.
Anakinra (KINERET®)           

Bevacizumab (AVASTIN®)           
Remarkable clone stability for at least 10 weeks of cultivation.
Certolizumab (CIMZIA®)           

Darbepoetin alfa (Aranesp®)           
Isolectical focusing (IEF) of Darbepoetin alfa biosimilar and Aranesp(&copy) originator.
Eculizumab (SOLIRIS®)           
Very good biosimilarity achieved in a challenging project (IgG2/4 hybrid antibody). 
Etanercept (ENBREL®)           

Ipilimumab (YERVOY®)           

Laronidase (ALDURAZYME®)           

Natalizumab (TYSABRI®)           
No commercial license is needed for application of host cell line and vector Technology - for Commercial manufacturing!
Nivolumab (OPDIVO®)           
A product concentration over 3 g/L has been obtained during a consistency run in stirred bioreactors.
Pembrolizumab (KEYTRUDA®)           
Pembrolizumab project (IgG4) finalized in a very short time - new revised workflow successfully applied!
Pertuzumab (PERJETA®)           
Outstanding productivity. >5g/L reached!
Vedolizumab Pools (ENTYVIO®)           
Pool stage finalized - Can be completed up to stable clone (RCB) in a very short time: Less than 4 months!

Cell Banks - under development

Alirocumab (PRALUENT®)           

Dupilumab (DUPIXENT®)           

Imiglucerase (CEREZYME®)           

Mepolizumab (NUCALA®)           

Omalizumab (XOLAIR®)           

Mock Cell LinesMock Cell Line

CHO Mock Cell Lines - on request

Contact us!

UGA Biopharma GmbH
16761 Hennigsdorf, Neuendorfstraße 20a (Germany)
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49 (0)3302 / 2024900